A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Open accessThe DOI matches its Crossref record; 121 of the 127 references it cites were found in a registry or an index; 18 of the 86 sources its claims cite were checked for support.
Abstract
The process of stopping antipsychotics may be causally related to relapse, potentially linked to neuroadaptations that persist after cessation, including dopaminergic hypersensitivity. Therefore, the risk of relapse on cessation of antipsychotics may be minimized by more gradual tapering. There is converging evidence that suggests that adaptations to antipsychotic exposure can persist for months or years after stopping the medication-from animal studies, observation of tardive dyskinesia in patients, and the clustering of relapses in this time period after the cessation of antipsychotics. Furthermore, PET imaging demonstrates a hyperbolic relationship between doses of antipsychotic and D2 receptor blockade. We, therefore, suggest that when antipsychotics are reduced, it should be done gradually (over months or years) and in a hyperbolic manner (to reduce D2 blockade "evenly"): ie, reducing by one quarter (or one half) of the most recent dose of antipsychotic, equivalent approximately to a reduction of 5 (or 10) percentage points of its D2 blockade, sequentially (so that reductions become smaller and smaller in size as total dose decreases), at intervals of 3-6 months, titrated to individual tolerance. Some patients may prefer to taper at 10% or less of their most recent dose each month. This process might allow underlying adaptations time to resolve, possibly reducing the risk of relapse on discontinuation. Final doses before complete cessation may need to be as small as 1/40th a therapeutic dose to prevent a large decrease in D2 blockade when stopped. This proposal should be tested in randomized controlled trials.
Overview
CoChat Summary
TL;DR
The paper proposes that antipsychotics should be tapered gradually over months or years and in a hyperbolic manner—reducing by fractions of the most recent dose that correspond to roughly even decrements in D2 receptor blockade—to minimize withdrawal-related relapse. It argues this hypothesis is supported by converging evidence on dopamine supersensitivity, tardive dyskinesia, relapse clustering after cessation, and PET dose-occupancy relationships, but it has not been tested in randomized controlled trials.
Key findings
- The authors recommend reductions of one quarter or one half of the most recent antipsychotic dose, approximately equivalent to 5 or 10 percentage-point reductions in D2 blockade, at intervals of 3–6 months, titrated to individual tolerance; some patients may prefer reductions of 10% or less of the most recent dose each month.
- Final doses before complete cessation may need to be as small as 1/40th of a therapeutic dose to avoid a large drop in D2 blockade when stopped.
- A meta-analysis cited by the authors found relapse rates over the next year of 77% after abrupt stopping, 57% after stopping over 1–2 weeks, 47% after 3–10 weeks, and 31% after tapering longer than 10 weeks.
- PET data show a hyperbolic dose–D2 occupancy relationship; for haloperidol, linear dose reductions from 4 mg produce increasingly large occupancy drops: 3.5 percentage points from 4 to 3 mg, 6.1 from 3 to 2 mg, 13.7 from 2 to 1 mg, and 55.7 from 1 to 0 mg.
Methods
- Narrative review and hypothesis paper synthesizing animal studies, human PET imaging, case reports, observational studies, and randomized discontinuation trials; no new primary data are collected.
- The authors review relapse patterns after antipsychotic discontinuation, evidence on tardive dyskinesia and dopaminergic hypersensitivity, and PET-derived dose–D2 occupancy relationships.
- They use Emax equations of the form y = maximal occupancy × x/(x + ED50) to derive hyperbolic tapering schedules for six antipsychotics, with doses rounded and intended to be individualized.
Limitations
- The paper states that PET studies have relatively small sample sizes and may not capture individual variation, though the hyperbolic shape of the dose–activity curve is expected to be universal; heterogeneity in PET meta-analyses suggests interindividual differences in receptor occupancy for a given dose.
- The paper states that it is difficult to determine whether D2 occupancy linearly corresponds to withdrawal effects, and that other receptor targets such as 5HT2, 5HT1A, and cholinergic receptors may also determine withdrawal effects, particularly for clozapine.
- The text makes evident that the proposed tapering method is a hypothesis not yet tested in randomized controlled trials; the authors explicitly state that it should be tested in further tapering trials, and the figures’ time frames are described as theoretical, based on few small studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
14 Valid · 3 Not valid · 35 Not checked · 19 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“That is, relapses are not distributed evenly across time but tend to occur predominantly around the point of drug cessation.”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis in Patients With Schizophrenia
What the sources say
- Not checked — no full text of the sourcecites [3] Viguera, 1997, Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment, Arch Gen Psychiatry. source
- Not checked — no full text of the sourcecites [56] Leucht, 2012, Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis, Lancet. source
- Not checked — no full text of the sourcecites [57] Wunderink, 2013, Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial, JAMA Psychiatry. source
- Not checked — no full text of the sourcecites [58] Mayoral-van Son, 2016, Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study, J Clin Psychiatry. source
- Disputedcites [59] Chen, 2010, Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial, BMJ. sourceExperimental — accuracy not yet measured
The Results (Primary outcome: relapse; page not provided) report that only 23 of 83 relapses occurred within 60 days of randomisation; 60 occurred later. The Methods (Statistical analysis; page not provided) identify those first 60 days as the period when relapse might be related to switching medication. The reported relapses therefore did not occur predominantly around drug cessation. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Upon the removal of blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.7,23”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
What the sources say
- Partly supportedcites [7] Moncrieff, 2015, Antipsychotic maintenance treatment: time to rethink, PLoS Med. sourceExperimental — accuracy not yet measured
The Evidence for Maintenance Therapy section says antipsychotic withdrawal may make relapse more likely in people with schizophrenia. It does not describe persistently increased presynaptic DSC or an interaction with elevated postsynaptic sensitivity; searches for those mechanisms found no supporting passage. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [23] Chouinard, 2017, Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy, Psychother Psychosom. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Meta-analysis of molecular imaging studies in schizophrenia found increased D2/D3 receptor availability only in those subjects who had been exposed to antipsychotic medication but not in antipsychotic-naïve patients.38”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Neurobiology of Antipsychotic Withdrawal Syndrome
What the sources say
- Supportedcites [38] Howes, 2012, The nature of dopamine dysfunction in schizophrenia and what this means for treatment, Arch Gen Psychiatry. source
The Dopamine receptors section (p. 6) reports a significant difference in D2/3 receptor availability in studies including previously treated patients, but no significant difference in studies exclusively of antipsychotic-naïve patients. The Methodological considerations section (p. 8) likewise says the small elevation was not present in drug-naïve patients, while cautioning that those analyses had reduced power. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Schizophrenia is attributed to increased presynaptic dopaminergic synthesizing capacity (DSC)54”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
What the sources say
- Partly supportedcites [54] McCutcheon, 2018, Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis, Schizophr Bull. sourceExperimental — accuracy not yet measured
The Results (Studies of the Whole Striatum; page unavailable) report elevated presynaptic dopamine function in people with schizophrenia, including a significant elevation in studies using labeled L-DOPA. But the paper does not establish that increased dopamine synthesis capacity causes schizophrenia; the Discussion (The Anatomical Locus of Dopaminergic Dysfunction in Psychosis; page unavailable) says causality remains to be established. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In animals, dopaminergic blockade leads to dopaminergic hypersensitivity.35,36”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Neurobiology of Antipsychotic Withdrawal Syndrome
What the sources say
- Supportedcites [35] Samaha, 2007, “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time, J Neurosci. source
The Introduction describes antipsychotics as antidopaminergic treatment and reports increased responses to dopamine agonists in laboratory animals after chronic treatment. The Discussion also reports dopamine supersensitivity during ongoing haloperidol treatment in animals. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [36] Joyce, 2001, D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: influence of withdrawal period, Synapse source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
41 more claims · 6 with their cited sources checked
Create a free account to see all 71 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Horowitz-Taylor method for personalised tapering of psychiatric medication recognises that tapering should be ‘hyperbolic’ to achieve a linear reduction of receptor occupancy to prevent withdrawal,9,15”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [15]
Experimental — accuracy not yet measuredIn the citing paper
“The Horowitz–Taylor method for personalised tapering of psychiatric medication recognises that tapering should be ‘hyperbolic’ to achieve a linear reduction of receptor occupancy to prevent withdrawal,11,13”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“Table: Table 1. Case studies reporting psychotic symptoms following abrupt cessation of dopamine antagonists prescribed for reasons other than treating psychosis in patients with no history of primary psychotic symptoms”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“Fluphenazine for acute drug-induced psychosis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“Eight case reports describe psychotic symptoms arising in 13 patients with no history of psychosis after the abrupt withdrawal of dopamine antagonists (table 1).”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Withdrawal-Associated Psychosis
“26 M BPAD with brief DIP and no other psychotic symptoms | Fluphenazine for acute drug-induced psychosis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Evidence for Prolonged Tapering
“Table: Table 2 Randomized controlled trials examining discontinuation (DS) groups vs maintained (MT) groups (n.s. = no significant difference; N/A = not available)”
§ A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse > Introduction > Evidence for Prolonged Tapering
“however, this last study was not randomized, meaning selection bias is possible”
Citations
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
The Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Self-citationHowes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Lehman, A. F., Steinwachs, D. M., & The Co-Investigators of the PORT Project (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033302 · Cited by 910
Schizophrenia, dopamine and the striatum: From biology to symptoms
McCutcheon, R. A., Abi-Dargham, A., & Howes, O. D. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.004 · Cited by 763
Comparing rat’s to human’s age: How old is my rat in people years?
Quinn, R. (2005) · Nutrition · doi:10.1016/j.nut.2005.04.002 · Cited by 682
Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.19 · Cited by 567
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520
II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment
Crow, T. J., MacMillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.148.2.120 · Cited by 491
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392
5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Silvestri, S., Seeman, M. V., Negrete, J.-C., Houle, S., Shammi, C. M., Remington, G. J., Kapur, S., Zipursky, R. B., Wilson, A. A., Christensen, B. K., et al. (2000) · Psychopharmacology · doi:10.1007/s002130000532 · Cited by 311
McCutcheon, R., Beck, K., Jauhar, S., & Howes, O. D. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx180 · Cited by 305
Self-citationAmerican Psychiatric Association (2020) · doi:10.1176/appi.books.9780890424841 · Cited by 302
Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301
The Maudsley Prescribing Guidelines in Psychiatry (Full-Text Access)
(2025) · The Maudsley Prescribing Guidelines in Psychiatry · doi:10.1002/9781119870203.mpg016 · Cited by 290
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Self-citationVita, A., De Peri, L., Deste, G., Barlati, S., & Sacchetti, E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.008 · Cited by 275
Dopaminergic supersensitivity after neuroleptics: time-course and specificity
Muller, P., & Seeman, P. (1978) · Psychopharmacology · doi:10.1007/bf00429171 · Cited by 271
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Tardive Dyskinesia: Prevalence, Incidence, and Risk Factors
KANE, J. M., WOERNER, M., & LIEBERMAN, J. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198808001-00010 · Cited by 266
Samaha, A.-N., Seeman, P., Stewart, J., Rajabi, H., & Kapur, S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5416-06.2007 · Cited by 262
Clinical pharmacology of atypical antipsychotics: an update
Mauri, M. C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., & Altamura, A. C. (2014) · Technische Universität Dortmund · doi:10.17877/de290r-7037 · Cited by 250
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., & Taylor, D. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.182683 · Cited by 244
Self-citationWunderink, L., Nienhuis, F. J., Sytema, S., Slooff, C. J., Knegtering, R., & Wiersma, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0502 · Cited by 234
Moncrieff, J. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00787.x · Cited by 231
Fluphenazine vs Placebo in Patients With Remitted, Acute First-Episode Schizophrenia
Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290010048009 · Cited by 222
Carbon, M., Kane, J. M., Leucht, S., & Correll, C. U. (2018) · World Psychiatry · doi:10.1002/wps.20579 · Cited by 214
Bain, K. T., Holmes, H. M., Beers, M. H., Maio, V., Handler, S. M., & Pauker, S. G. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01916.x · Cited by 198
Tiihonen, J., Tanskanen, A., & Taipale, H. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17091001 · Cited by 196
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
Tardive Dyskinesia: Prevalence, Incidence, and Risk Factors
Kane, J. M., Woerner, M. G., & Lieberman, J. A. (1985) · Psychopharmacology series · doi:10.1007/978-3-642-70140-5_9 · Cited by 161
Chen, E. Y. H., Hui, C. L. M., Lam, M. M. L., Chiu, C. P. Y., Law, C. W., Chung, D. W. S., Tso, S., Pang, E. P. F., Chan, K. T., Wong, Y. C., et al. (2010) · BMJ · doi:10.1136/bmj.c4024 · Cited by 151
Voineskos, A. N., Mulsant, B. H., Dickie, E. W., Neufeld, N. H., Rothschild, A. J., Whyte, E. M., Meyers, B. S., Alexopoulos, G. S., Hoptman, M. J., Lerch, J. P., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.0036 · Cited by 132
Bockting, C. L. H., Klein, N. S., Elgersma, H. J., van Rijsbergen, G. D., Slofstra, C., Ormel, J., Buskens, E., Dekker, J., de Jong, P. J., Nolen, W. A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30100-7 · Cited by 130
Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis
Lako, I. M., van den Heuvel, E. R., Knegtering, H., Bruggeman, R., & Taxis, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182983ffa · Cited by 125
The Scottish first episode schizophrenia study: VII. Two‐year follow‐up
Scottish Schizophrenia Research Group, McCreadie, R. G., Wiles, D., Grant, S., Crockett, G. T., Mahmood, Z., Livingston, M. G., Watt, J. A. G., Greene, J. G., Kershaw, P. W., et al. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb03032.x · Cited by 120
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
Tardive dyskinesia: are first signs reversible?
(1977) · American Journal of Psychiatry · doi:10.1176/ajp.134.1.84 · Cited by 114
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
The Maudsley Prescribing Guidelines in Psychiatry, 12th ed
Jenkins, J. A., & Kontos, N. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16bk10716 · Cited by 107
Isupova, O. G. (2011) · International Journal of Qualitative Studies on Health and Well-being · doi:10.3402/qhw.v6i3.5907 · Cited by 106
Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication
Glazer, W. M., Morgenstern, H., Schooler, N., Berkman, C. S., & Moore, D. C. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.157.4.585 · Cited by 106
Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal
Shiovitz, T. M., Welke, T. L., Tigel, P. D., Anand, R., Hartman, R. D., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.591 · Cited by 104
Uchida, H., Takeuchi, H., Graff-Guerrero, A., Suzuki, T., Watanabe, K., & Mamo, D. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218d339 · Cited by 94
Gaebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., Lemke, M., Heuser, I., Maier, W., Huff, W., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05459yel · Cited by 92
Tadokoro, S., Okamura, N., Sekine, Y., Kanahara, N., Hashimoto, K., & Iyo, M. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr006 · Cited by 92
Weiden, P. J., Kim, E., Bermak, J., Turkoz, I., Gopal, S., & Berwaerts, J. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11308 · Cited by 90
Mizrahi, R., Agid, O., Borlido, C., Suridjan, I., Rusjan, P., Houle, S., Remington, G. J., Wilson, A. A., & Kapur, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.005 · Cited by 85
Drug discontinuation effects are part of the pharmacology of a drug
Reidenberg, M. M. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183285 · Cited by 82
Antipsychotic maintenance treatment: time to rethink
Moncrieff, J. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001861 · Cited by 80
Alvarez-Jimenez, M., O’Donoghue, B., Thompson, A., Gleeson, J. F., Bendall, S., Gonzalez-Blanch, C., Killackey, E., Wunderink, L., & McGorry, P. D. (2016) · CNS Drugs · doi:10.1007/s40263-016-0331-x · Cited by 80
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77
Self-citationMorant, N., Azam, K., Johnson, S., & Moncrieff, J. (2018) · Journal of Mental Health · doi:10.1080/09638237.2017.1370637 · Cited by 75
Jauhar, S., Veronese, M., Nour, M. M., Rogdaki, M., Hathway, P., Natesan, S., Turkheimer, F., Stone, J., Egerton, A., McGuire, P., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.07.003 · Cited by 75
Self-citationMcGorry, P., Alvarez-Jimenez, M., & Killackey, E. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.264 · Cited by 73
Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases
Houston, M. C., & Hodge, R. (1988) · American Heart Journal · doi:10.1016/0002-8703(88)90627-8 · Cited by 72
Zutshi, D., Cloud, L. J., & Factor, S. A. (2014) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.199 · Cited by 71
Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine
Meltzer, H. Y., Lee, M. A., Ranjan, R., Mason, E. A., & Cola, P. A. (1996) · Psychopharmacology · doi:10.1007/bf02245619 · Cited by 67
Zutshi, D., Factor, S., & Cloud, L. J. (2014) · PubMed · doi:10.7916/d85h7dzx · Cited by 66
Bowtell, M., Ratheesh, A., McGorry, P., Killackey, E., & O'Donoghue, B. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.11.010 · Cited by 62
Mayoral-van Son, J., de la Foz, V. O.-G., Martinez-Garcia, O., Moreno, T., Parrilla-Escobar, M., Valdizan, E. M., & Crespo-Facorro, B. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09540 · Cited by 60
What do individuals with schizophrenia need to increase their well-being
Gunnmo, P., & Fatouros‐Bergman, H. (2011) · International Journal of Qualitative Studies on Health and Well-Being · doi:10.3402/qhw.v6i1.5412 · Cited by 59
Bogers, J. P. A. M., Hambarian, G., Walburgh Schmidt, N., Vermeulen, J. M., & de Haan, L. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac138 · Cited by 58
Clozapine withdrawal rebound psychosis.
Borison, R. L., Diamond, B. I., Sinha, D., Gupta, R. P., & Ajiboye, P. O. (1988) · PubMed · Cited by 56
Littleton, J. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.961877.x · Cited by 55
Historical perspectives on tardive dyskinesia
Caroff, S. N., Ungvari, G. S., & Cunningham Owens, D. G. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.02.015 · Cited by 55
Neuroleptic discontinuation syndromes
Tranter, R., & Healy, D. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200412 · Cited by 54
SSRI and SNRI withdrawal symptoms reported on an internet forum
Stockmann, T., Odegbaro, D., Timimi, S., & Moncrieff, J. (2018) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-180018 · Cited by 54
Yilmaz, Z., Zai, C. C., Hwang, R., Mann, S., Arenovich, T., Remington, G., & Daskalakis, Z. J. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.027 · Cited by 52
McCreadie, R. G., Wiles, D. H., Grant, S. M., Moore, J. W., Crocket, G. T., Mahmood, Z., Livingston, M. G., Watt, J. A. G., Greene, J. G., Kershaw, P. W., et al. (1988) · British Journal of Psychiatry · doi:10.1192/bjp.152.4.470 · Cited by 52
Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation
Cooper, R. E., Hanratty, É., Morant, N., & Moncrieff, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218711 · Cited by 49
Tapering antipsychotic treatment
Horowitz, M. A., Murray, R. M., & Taylor, D. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.2166 · Cited by 49
Self-citationDetermining the optimal dose of haloperidol in first-episode psychosis
Oosthuizen, P., Emsley, R. A., Turner, J., & Keyter, N. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500403 · Cited by 48
Joyce, J. N. (2001) · Synapse · doi:10.1002/syn.1035 · Cited by 47
Thompson, A., Winsper, C., Marwaha, S., Haynes, J., Alvarez-Jimenez, M., Hetrick, S., Realpe, A., Vail, L., Dawson, S., & Sullivan, S. A. (2018) · BJPsych Open · doi:10.1192/bjo.2018.17 · Cited by 44
抗精神病薬8剤の用量に対するドーパミンD 2 受容体占有率の推定: メタ分析
Irene, M. L., Edwin, R. V. D. H., Knegtering, H., Bruggeman, R., & Katja, T. (2013) · Journal of Clinical Psychopharmacology · Cited by 44
Moncrieff, J., Gupta, S., & Horowitz, M. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320937910 · Cited by 43
Neuroleptic malignant syndrome after neuroleptic discontinuation
Amore, M., & Zazzeri, N. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00269-3 · Cited by 42
Franks, M., Macritchie, K., Mahmood, T., & Young, A. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107085238 · Cited by 39
(2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100730-04 · Cited by 38
Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design
Dixon, L. B., Thaker, G. K., Conley, R. R., Ross, D. E., Cascella, N. G., & Tamminga, C. A. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90061-m · Cited by 38
Boonstra, G., Burger, H., Grobbee, D. E., & Kahn, R. S. (2011) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2010.534801 · Cited by 38
Huhn, M., Leucht, C., Rothe, P., Dold, M., Heres, S., Bornschein, S., Schneider-Axmann, T., Hasan, A., & Leucht, S. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01109-y · Cited by 38
Potential Adverse Effects of Discontinuing Psychotropic Drugs: Part 2: Antidepressant Drugs
(2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100527-98 · Cited by 35
Pharmacodynamic principles and the time course of delayed and cumulative drug effects
Holford, N. (2018) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2018.26.2.56 · Cited by 35
Deprescribing antipsychotics: a guide for clinicians
Gupta, S., Cahill, J. D., & Miller, R. (2018) · BJPsych Advances · doi:10.1192/bja.2018.2 · Cited by 35
Outcome of antidepressant drug discontinuation with taperingstrips after 1–5 years
Groot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320954609 · Cited by 35
Emsley, R., Nuamah, I., Gopal, S., Hough, D., & Fleischhacker, W. W. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11874 · Cited by 34
Is tardive dyskinesia a unique disorder?
Marsden, C. D. (1985) · Psychopharmacology Supplementum · doi:10.1007/978-3-642-70140-5_8 · Cited by 33
Bogers, J. P. A. M., Hambarian, G., Michiels, M., Vermeulen, J., & de Haan, L. (2020) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa002 · Cited by 33
Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia
Roy-Desruisseaux, J., Landry, J., Bocti, C., Tessier, D., Hottin, P., & Trudel, J.-F. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q214 · Cited by 32
Jauhar, S., & Howes, O. D. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1357 · Cited by 32
Self-citationWithdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation
Schultz, S. K., Miller, D. D., Arndt, S., Ziebell, S., Gupta, S., & Andreasen, N. C. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00082-8 · Cited by 29
Landolt, K., Rössler, W., Ajdacic-Gross, V., Derks, E. M., Libiger, J., Kahn, R. S., & Fleischhacker, W. W. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.046 · Cited by 28
Neuroleptic‐induced supersensitivity psychosis in patients with bipolar affective disorder
Steiner, W., Laporta, M., & Chouinard, G. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05477.x · Cited by 26
How high is the relapse rate in schizophrenia?
Johnstone, E. C., & Geddes, J. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05858.x · Cited by 26
Neurobiology and principles of addiction and tolerance
Turton, S., & Lingford-Hughes, A. (2016) · Medicine · doi:10.1016/j.mpmed.2016.09.007 · Cited by 24
Serendipity and Psychopharmacology
Howland, R. H. (2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100903-01 · Cited by 24
Reserpine Withdrawal Psychosis
Kent, T. A., & WILBER, R. D. (1982) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198208000-00011 · Cited by 20
Liu, C.-C., & Takeuchi, H. (2020) · CNS Drugs · doi:10.1007/s40263-019-00682-8 · Cited by 19
Reserpine withdrawal psychosis: the possible role of denervation supersensitivity of receptors.
Kent, T. A., & Wilber, R. D. (1982) · PubMed · Cited by 18
Atypical antipsychotic withdrawal dyskinesia in 4 patients with mood disorders
Urbano, M., Spiegel, D., & Rai, A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815a5870 · Cited by 17
Psychosis after neuroleptic withdrawal in a manic-depressive patient
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.1.105 · Cited by 16
Five year outcomes of tapering antipsychotic drug doses in a community mental health center
Steingard, S. (2018) · Community Mental Health Journal · doi:10.1007/s10597-018-0313-1 · Cited by 15
Increasing expectations and knowledge require a more subtle use of prophylactic antipsychotics
Murray, R. M., & Forti, M. D. (2018) · World Psychiatry · doi:10.1002/wps.20517 · Cited by 13
Self-citationSPECT technique for visualization of cerebral dopamine D2 receptors
Konig, P., Benzer, M., & Fritzche, H. (1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1607a · Cited by 12
Perényi, A., Frecska, E., Bagdy, G., & Révai, K. (1985) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1985.tb02636.x · Cited by 11
Psychiatric hospitalization following antipsychotic medication cessation in first episode psychosis
Hayes, J. F., Osborn, D. P., Lundin, A., & Dalman, C. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119827883 · Cited by 8
Psychotropic discontinuation leading to an NMS‐like condition
Kurien, R., & Vattakatuchery, J. J. (2013) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.297 · Cited by 6
De novo treatment-resistant psychosis following thioridazine withdrawal
Bastiampillai, T. J., Fantasia, R., & Nelson, A. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413499943 · Cited by 4
Adolescent female with withdrawal psychosis following abrupt termination of ziprasidone
Jacob, M. K., Ash, P., & Craighead, W. E. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0239-z · Cited by 3
Chapter 3. Guideline Statements and Implementation
(2020) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890424841.schizophrenia03 · Cited by 2
Research works printed but not linked: 4
- McGorry, 2013, Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more, JAMA Psychiatry., 70, 898, 10.1001/jamapsychiatry.2013.264 · DOI · Paper page
- Seeman, 2014, Yes, Breast is best but taper domperidone when stopping (e-letter), Br J Gen Pract.
- American Psychiatric Association, 2020, Guideline statements and implementation., 312
- Lehman, 2004, Practice guideline for the treatment of partients with schizophrenia, Am J Psychiatry, 161, 1
Cited by
Leucht, S., Priller, J., & Davis, J. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240738 · Cited by 117
Moncrieff, J., Crellin, N., Stansfeld, J., Cooper, R., Marston, L., Freemantle, N., Lewis, G., Hunter, R., Johnson, S., Barnes, T., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00258-4 · Cited by 90
Self-citationINTEGRATE: international guidelines for the algorithmic treatment of schizophrenia
McCutcheon, R. A., Pillinger, T., Varvari, I., Halstead, S., Ayinde, O. O., Crossley, N. A., Correll, C. U., Hahn, M., Howes, O. D., Kane, J. M., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00031-8 · Cited by 115
Self-citationThe expanding role of somatostatin analogs in the management of neuroendocrine tumors.
Wolin, E. M. (2012) · Europe PMC (PubMed Central) · Cited by 126
(2022) · doi:10.1192/bja.2021.62 · Cited by 73
Self-citation
Metadata
- Authors
- Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D.
- Affiliations
- Goodmayes Hospital (GB)
- King's College London (GB)
- Corresponding author
- Horowitz, Mark Abie
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-23
- Volume
- 47
- Issue
- 4
- Pages
- 1116-1129
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC8266572
- OpenAlex
- W3137682600
- Semantic Scholar
- a855858cd020d93218767ac4e43fbf07848933a0
- Cited by
- 157
- References
- 127
- Citations by year
- 2026: 28 · 2025: 33 · 2024: 24 · 2023: 32 · 2022: 24 · 2021: 15
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Schizophrenia Bulletin (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Funders
- North East London NHS Foundation Trust
- Royal College of Physicians of Edinburgh
- National Institute for Health Research Biomedical Research Centre
- South London and Maudsley NHS Foundation Trust
- King’s College London
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- antipsychotic tapering, antipsychotic discontinuation
- MeSH terms
- Drug Administration Schedule, Female, Humans, Male, Recurrence, Schizophrenia, Antipsychotic Agents, Risk Assessment, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.